Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:bfsLayer |
2
|
| gptkbp:bfsParent |
gptkb:physicist
|
| gptkbp:activities |
factor VIII replacement
|
| gptkbp:approves |
sterile water for injection
|
| gptkbp:availability |
prescription only
|
| gptkbp:category |
gptkb:physicist
|
| gptkbp:class |
gptkb:weapon
|
| gptkbp:clinical_trial |
Phase III
ongoing studies treatment of bleeding episodes |
| gptkbp:contraindication |
known hypersensitivity to components
|
| gptkbp:dosage_form |
lyophilized powder
based on body weight |
| gptkbp:duration |
as needed
|
| gptkbp:education |
recognition of bleeding symptoms
|
| gptkbp:effective_date |
gptkb:1993
FDA approved |
| gptkbp:formulation |
powder for reconstitution
|
| gptkbp:frequency |
every 2 to 3 days
|
| gptkbp:healthcare |
injectable solution
hemophilia specialist |
| https://www.w3.org/2000/01/rdf-schema#label |
Kogenate
|
| gptkbp:indication |
prophylaxis of bleeding episodes
|
| gptkbp:ingredients |
gptkb:character
|
| gptkbp:interacts_with |
anticoagulants
|
| gptkbp:is_effective_against |
effective in reducing bleeding
|
| gptkbp:is_monitored_by |
factor VIII levels
factor levels and bleeding episodes |
| gptkbp:is_used_for |
gptkb:hemophilia_A
|
| gptkbp:label |
FDA guidelines
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Baxter_International
|
| gptkbp:market |
adverse event reporting
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
half-life of 12 hours
restores factor VIII levels |
| gptkbp:population |
children and adults
|
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
gptkb:National_Hemophilia_Foundation
individualized treatment plans |
| gptkbp:regulatory_compliance |
important for treatment success
marketed in multiple countries |
| gptkbp:research_focus |
gene therapy alternatives
|
| gptkbp:safety_features |
generally well tolerated
monitor for inhibitors |
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:setting |
home or clinical setting
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
allergic reactions
thromboembolic events |
| gptkbp:storage |
refrigerated
|
| gptkbp:supply_chain |
managed by manufacturer
|
| gptkbp:target_audience |
patients with hemophilia A
|
| gptkbp:technique |
IV infusion
|
| gptkbp:traded_on |
Kogenate FS
|
| gptkbp:treatment |
improved quality of life
surgical procedures factor replacement therapy prevent bleeding complications |
| gptkbp:type_of_care |
critical for efficacy
|